CULLINAN THERAPEUTICS, INC. Capital Expenditures
CULLINAN THERAPEUTICS, INC. (CGEM) reported Capital Expenditures of $49.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-03-10
- CULLINAN THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $11.00K.
- CULLINAN THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2024-12-31 was $0.00.
- CULLINAN THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2024-09-30 was $0.00.
- CULLINAN THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- CULLINAN THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2025 was $49.00K.
- CULLINAN THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- CULLINAN THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2023 was $208.00K, a 81.64% decline from fiscal 2022.
- CULLINAN THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2022 was $1.13M.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2025-12-31 | $11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $49.00K 10-K · filed 2026-03-10 | ||
| 2025-09-30 | $38.00K 10-Q · filed 2025-11-06 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $0.00 derived: sum of 2 quarters · filed 2026-03-10 | $0.00 derived: sum of 3 quarters · filed 2026-03-10 | $0.00 10-K · filed 2026-03-10 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | $0.00 derived: sum of 3 quarters · filed 2025-02-27 | $0.00 derived: sum of 4 quarters · filed 2025-02-27 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-15 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $0.00 derived: sum of 3 quarters · filed 2025-02-27 | $49.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $49.00K derived: sum of 3 quarters · filed 2025-02-27 | $208.00K 10-K · filed 2025-02-27 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $49.00K derived: sum of 2 quarters · filed 2024-11-07 | $208.00K 10-Q · filed 2024-11-07 | $1.09M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $49.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $208.00K 10-Q · filed 2024-08-08 | $1.09M derived: sum of 3 quarters · filed 2024-08-08 | $1.34M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $159.00K 10-Q · filed 2024-05-15 | $1.04M derived: sum of 2 quarters · filed 2024-05-15 | $1.29M derived: sum of 3 quarters · filed 2024-05-15 | $1.29M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $882.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $1.13M derived: sum of 2 quarters · filed 2024-03-14 | $1.13M derived: sum of 3 quarters · filed 2024-03-14 | $1.13M 10-K · filed 2024-03-14 |
| 2022-09-30 | $251.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $251.00K derived: sum of 2 quarters · filed 2023-11-08 | $251.00K 10-Q · filed 2023-11-08 | $251.00K derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | $0.00 derived: sum of 3 quarters · filed 2023-08-10 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | $0.00 derived: sum of 2 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $0.00 10-K · filed 2023-03-09 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $3.00K derived: sum of 2 quarters · filed 2022-03-17 | $7.00K derived: sum of 3 quarters · filed 2022-03-17 | $10.00K 10-K · filed 2022-03-17 |
| 2020-09-30 | $4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $8.00K derived: sum of 2 quarters · filed 2021-11-09 | $11.00K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $7.00K 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $3.00K 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |